Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.
It is no coincidence that Italy is often described as “the land of a hundred bell towers.” While this expression is sometimes ...
Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) quickly reached blockbuster status within their ...
If you have an event coming up that you would like highlighted, you can email Destiny at [email protected].
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback